课题基金 / 基金详情

CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) as a Resource

CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) as a Resource
CNS HIV 抗逆转录病毒治疗效果研究 (CHARTER) 作为资源
批准号:
8329592
负责人:
IGOR GRANT
金额:
$31.4万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-16 至 2015-09-15

项目摘要

项目成果

IGOR GRANT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The CNS HIV Antiretroviral Therapy Effects Research (CHARTER) was funded in September 2002 in response to RFA NIMH-00-AI-0005 with the aim of exploring the changing presentation of HIV neurological complications in the context of highly active antiretroviral therapy (HAART). CHARTER's major aims were to determine how central and peripheral nervous system complications of HIV were being affected by different histories and regimens of ART. Over the past 8 years, the six-site CHARTER project has accumulated invaluable clinical and research data on 1598 participants, with longitudinal data being collected on 674 of these participants. Data includes neuromedical characterization, neuropsychological functioning, psychiatric and drug abuse variables, treatment data, brain imaging, and viral and host genetics information. Each CHARTER visit generates approximately 4000 individual variables; currently the database contains over 5 million datapoints. A key component of CHARTER is to serve as a catalyst for additional studies/analyses by making this wealth of data available to investigators. To date, the CHARTER Coordinating Core and CHARTER Resource have facilitated research requests for 70 investigators across 18 institutions. In order to continue to make samples and data available to the neuroAIDS community, we propose to extend the ¿CHARTER as a Resource¿ facilities beyond the original CHARTER Option Period.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Obstructive Sleep Apnea Endotypes and Impact on Phenotypes of People Living with HIV
Heroin abstinence induced HPA & SAM dysregulation disrupts HIV virologic control
Heroin abstinence induced HPA & SAM dysregulation disrupts HIV virologic control
California NeuroAIDS Tissue Network
海外基金